Skip to main content

Table 4 Incidence of Peripheral Neuropathy during Treatment Cycles

From: Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients

< 70 Years (n = 14)

Cycles

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

Grade1

3

4

6

7

9

8

7

6

6

5

2

2

2

1

1

0

0

Grade2

0

1

1

1

1

2

0

1

1

2

4

3

2

1

1

1

0

Grade3

0

0

0

0

0

0

0

0

0

0

0

1

0

0

0

0

1

n

14

13

12

11

11

11

9

8

7

7

6

6

4

2

2

2

1

≥ 70 Years (n = 8)

Grade1

1

4

6

5

4

4

6

4

4

2

2

1

1

0

0

0

0

Grade2

1

1

0

0

1

1

0

1

0

2

1

1

1

1

0

0

0

Grade3

0

0

0

0

0

0

0

0

0

0

0

0

0

1

0

0

0

n

8

8

8

7

6

6

6

5

5

4

3

2

2

2

1

0

0

  1. Grades of adverse events were defined according to NCI-CTC v3.0
  2. *P values were calculated with the use of Fisher's exact probability test.
Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us